Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chemokine Therapeutics has received a certificate for clinical trial and medicinal test from the Hong Kong Department of Health allowing the company to begin a Phase II trial in liver cancer with its lead drug candidate, CTCE-9908.
Subscribe to our email newsletter
The company received FDA and Health Canada approval for the clinical trial earlier in 2008.
The Phase II trial will be an international, multi-center, randomized, controlled, open-label study assessing the efficacy and safety of CTCE-9908 that will include up to 132 patients with liver cancer.
The company also announced that Fundamental Research Corporation has initiated analyst coverage of the company.
Walter Korz, president and CEO of Chemokine Therapeutics, said: “Liver cancer is more prevalent in the Asian communities and working with Dr Ronnie Poon, principal investigator for Hong Kong, will help to expedite the patient recruitment process.”